An open randomized controlled study of topical B blocker gel for the treatment of infantile hemangioma: Comparison of safety and efficacy among topical 0%, 1% 5% B blocker gel.
Phase 2
- Conditions
- Infantile hemangioma
- Registration Number
- JPRN-UMIN000017148
- Lead Sponsor
- Chiba University
- Brief Summary
In the PPS, the main endpoint, the rate of change in the average number of brightness in the area where the tumor exists after 6 months, three groups are same, ie, 0.9. There was no difference. A difference in the average number of brightness in the area where the tumor exists after 6 months was examined. A tendency was observed that the number of brightness decreased.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 19
Inclusion Criteria
Not provided
Exclusion Criteria
Patients who have asthma, cardiovascular malformation, diabetes, medication (including adrenaline, beta-blocker, calcium antagonist agent, digitalis product, CYP2D6 inhibitor), other skin disease, many infant hemangioma, congenital hemangioma. Patients who are ruled unfit to this study.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method color of tumor
- Secondary Outcome Measures
Name Time Method